Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telmisartan - Boehringer Ingelheim/GlaxoSmithKline

X
Drug Profile

Telmisartan - Boehringer Ingelheim/GlaxoSmithKline

Alternative Names: BIBR277; Kinzal; Kinzalmono; Micardis; Pritor; PritorPlus; Telma; YM086

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Developer Abbott Laboratories; Astellas Pharma; Boehringer Ingelheim Pharma KG; Glenmark Pharmaceuticals Ltd; GSK; Nippon Boehringer Ingelheim
  • Class Antihypertensives; Benzimidazoles; Benzoates; Small molecules
  • Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Essential hypertension; Hypertension
  • No development reported Metabolic syndrome
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 30 Oct 2020 Astellas Pharma terminates its sales agreement for the Micardis family, prior to October 2020
  • 30 Oct 2017 Nippon Boehringer Ingelheim and Astellas Pharma extend agreement related to the sales of telmisartan (Micardis® family) in Japan
  • 07 Jan 2016 Boehringer Ingelheim and Astellas Pharma extend agreement related to sale and co-promotion of telmisartan (Micardis® family) in Japan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top